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Abstract
The detection of antinuclear autoantibody (ANA) is dependent on many factors and varies between the populations. The aim 
of the study was first to assess the prevalence of ANA in the Polish adult population depending on age, sex and the cutoff 
threshold used for the results obtained. Second, we estimated the occurrence of individual types of ANA-staining patterns. 
We tested 1731 patient samples using commercially available IIFA using two cutoff thresholds of 1:100 and 1:160. We found 
ANA in 260 participants (15.0%), but the percentage of positive results strongly depended on the cutoff level. For a cutoff 
threshold 1:100, the positive population was 19.5% and for the 1:160 cutoff threshold, it was 11.7%. The most prevalent 
ANA-staining pattern was AC-2 Dense Fine speckled (50%), followed by AC-21 Reticular/AMA (14.38%) ANA more com-
mon in women (72%); 64% of ANA-positive patients were over 50 years of age. ANA prevalence in the Polish population is 
at a level observed in other highly developed countries and is more prevalent in women and elderly individuals. To reduce 
the number of positive results released, we suggest that Polish laboratories should set 1:160 as the cutoff threshold.




AD  Autoimmune diseases
AMA  Antimitochondrial antibodies
ANA  Antinuclear antibody
BMI  Body mass index
CFPiP  College of Family Physician in Poland
CVDs  Cardiovascular diseases
DFS70  Dense fine speckled
Hep-2  Human laryngeal carcinoma cell line
ICAP  International Consensus on ANA patterns
IIFA  Indirect immunofluorescence assay
NAAbs  Natural autoantibodies
NuMA  Nuclear mitotic apparatus
PoLA  Polish Lipid Association
SARDs  Systemic autoimmune rheumatic diseases
WHR  Waist–hip ratio
Introduction
Autoimmune diseases (AD) are characterized by immune 
responses to self-antigens resulting in tissue damage or 
dysfunction. The response can be systemic or can affect 
specific organs or body systems [1]. AD include more 
than 80 diseases, of which systemic autoimmune rheu-
matic diseases (SARDs) are a particular group, with a 
very diverse clinical picture and complex pathogenetic 
mechanisms [1]. It is well known that SARDs mainly 
affect older people, and predominantly women [2–5]. At 
the same time, there are increasing cases of connective 
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tissue diseases in young people and even in children 
[6–8]. Thus far, the etiology of antinuclear antibody 
(ANA) formation has not been fully elucidated. There 
are many suspected factors that increase the risk of ANA 
biogenesis and occurrence, including genetic predisposi-
tion and environmental factors such as infections, oxida-
tive stress factors, physical and chemical agents, as well 
as stressful life events [4, 5, 9–11].
Laboratory diagnosis of SARDs is complicated by the 
requirement for specialized tests to enable detection of 
autoantibodies. For years, the indirect immunofluores-
cence assay (IIFA) has been regarded as the gold standard 
for measuring ANA. According to current recommenda-
tions, the human laryngeal carcinoma cell line (HEp-2) 
is a recommended substrate for detecting ANA, and each 
positive test result should include an estimated titer and 
fluorescence pattern [6]. The current recommendation for 
a positive ANA finding is a titer of ≥ 1:160 [6]. However, 
the IIFA assay ANA threshold titer is dependent on rea-
gents, equipment and other local factors, and hence the 
screening dilution should be defined locally.
A main feature of the screening test should be high 
sensitivity (which significantly reduces its specificity, 
i.e., the number of false-positive results increases—posi-
tive results are also obtained in people without symptoms 
of rheumatic disease) [12]. This means that the higher the 
antibody titer, the greater the likelihood that the result is 
clinically relevant and is associated with symptoms.
Autoimmunity is not always clinically symptomatic 
and can be observed in individuals without clinical 
manifestations of disease. In this case, so-called natural 
autoantibodies (NAAbs) can be observed in the patient’s 
serum, which bind with low avidity epitopes naturally 
existing in the patient’s body [13, 14]. In genetically pre-
disposed individuals, chronic activation of the immune 
system can lead to proliferation of autopolymerizing 
B-lymphocyte clones, increased autoantibody titres and 
finally to the development of clinical symptoms of auto-
immune disease [15, 16]. The prevalence of autoantibod-
ies in the general population has been estimated to be 
in the range 5.92–30.8%, but this wide range is mainly 
due to differences in the cutoff values used in the studies 
and the population studied, e.g., autoantibodies are more 
common in African-Americans and less common in the 
Chinese population. [2, 4, 17–22].
The aim of this study was first to assess the prevalence 
of ANA in the Polish population, taking into account age, 
sex and the cutoff threshold used for the results obtained. 
Second, we estimated the occurrence of individual types 
of ANA-staining patterns. As far as we are aware, similar 
large cohort population studies have not yet been con-
ducted in the Polish population.
Materials and methods
Design
A nationwide observational, cross-sectional study was car-
ried out in Poland in the fourth quarter of 2015 and the 
first and second quarters of 2016.
Sampling
This study is part of a large research program “Nation-
wide study of cardiovascular health in primary care in 
Poland—LIPIDOGRAM2015 and LIPIDOGEN2015”, the 
design and rationale of which have been described in detail 
previously [23]. Briefly, the recruitment was carried out 
by 438 physicians-investigators in 398 primary care prac-
tices recruited in 16 (of 17) voivodeships (major admin-
istrative region in Poland), in line with the operational 
structure created by previous studies [24, 25]. Physicians-
investigators were randomly selected from the Medical 
Data Management database. Each physician-investigator 
selected at least 30 patients in each Primary Health Care 
practice for participation in the LIPIDOGRAM2015 study. 
From each group of 30 patients, up to 4 patients were ran-
domly selected by the physician-investigator to participate 
in the LIPIDOGEN2015 sub-study. The expected num-
ber of patients recruited for LIPIDOGRAM2015 study 
(consecutive sample) was 13,000–14,000 with 13–15% 
(1700–2000) enrolled to the LIPIDOGEN2015 sub-study 
(random sample). The program covered only adult patients 
over 18 years old. For each patient recruited for the study, 
a 28-item questionnaire was collected containing data on 
chronic diseases and their treatment, lifestyle (diet, physi-
cal activity, smoking) and family history of cardiovascu-
lar diseases (CVDs) (24 questions in total). The question-
naire also included demographic data: age, gender, place 
of residence and level of education (4 questions in total). 
To avoid missing data, only the most important data ele-
ments were collected to minimize the burden and focus 
on routinely collected data. The questionnaire was tested 
with a group of 10 primary care physicians who had no 
comments or difficulties in completing it. Content validity 
was checked by comparing the questionnaire with other 
similar tools used in Poland (an English translation of the 
questionnaire can be found in the LIPIDOGRAM2015 
study design) [23]. Each questionnaire was labeled with an 
individual barcode, identical to the barcodes on samples of 
blood and saliva. Anthropometric measurements (height, 
body weight, waist circumference, and hip circumfer-
ence) were performed at the doctor’s office. In all enrolled 
patients, serum samples were obtained after ≥ 12 h of 
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fasting by collecting whole blood from an antecubital vein. 
On the same day, measurements of blood pressure, heart 
rate, and fasting glucose were obtained as well as lipid pro-
file samples. For the LIPIDOGEN2015 sub-study, saliva 
samples for DNA isolation and blood samples for measure-
ment of glycated hemoglobin, oxidative stress parameters, 
autoantibody levels, and inflammatory cytokine profile and 
apolipoprotein profile were collected.
For this study, we used 1731 serum samples from the 
abovementioned LIPIDOGEN2015 sub-study. The tested 
group included 1043 women and 688 men. The blood sam-
ples were transferred in cooled containers (−20 °C) to a 
central laboratory (Silesian Analytical Laboratories—SLA 
in Katowice, Poland) for biochemical analyses and then to 
the autoimmune laboratory (Euroimmun Poland Ltd. Cus-
tomer Training Laboratory in Wroclaw, Poland) for ANA 
determination.
Laboratory analyses of ANA
ANAs were detected by a IIFA using human laryngeal car-
cinoma cells (HEp-2) with commercially available Euro-
immun Medizinische Labordiagnostika AG (Lübeck, Ger-
many) test kits Mosaic Basic Profile 3 (catalogue number 
FC 1800-2010-3). Sample incubation was carried out manu-
ally, according to the instructions provided by the manu-
facturer of the test, except that 998 samples were diluted 
with a threshold cutoff 1:160 as recommended by the current 
guidelines [6] and 733 patient samples were diluted with 
a threshold cutoff 1:100 as recommended by the manufac-
turer’s instruction. The samples were randomly divided into 
two groups. The results were evaluated using a EUROstar III 
fluorescence microscope (CarlZeiss Oberkochen, Germany). 
The test results were evaluated by an experienced technician. 
The test result included a qualitative assessment of the pres-
ence of ANA, estimation of antibody titer, and determination 
of the characteristic pattern according to the International 
Consensus on ANA patterns (ICAP) nomenclature [26]. 
The results from IIFA were collected and stored as digital 
images.
Statistical analysis
Statistical analyses was carried out were performed using 
Statistica 13.3 (StatSoft, Tulsa, USA). Data are expressed 
as mean ± SD (for normal distribution) and median (non-
parametric distribution) for continuous variables, and as a 
percentage for categorical variables. Univariate comparison 
of markers related to autoimmune diseases according to clin-
ical variables was performed using the U-Mann–Whitney 
method for nonparametric variables or χ2 test/Fisher exact 
test where appropriate. A two-sided p < 0.05 was considered 
to indicate significance.
Results
The study included 1731 patients attending primary health 
care practices (1043 women and 688 men). 1098 people 
were diagnosed with hypertension, coronary artery disease, 
dyslipidemia, diabetes, atrial fibrillation, kidney disease 
or stroke. 649 people were apparently healthy individuals. 
The mean age of participants was 51 ± (SD 13 years) and 
60.25% were female (Table 1). The body mass index (BMI) 
indicated that the participants were on average slightly over-
weight [27], and the average waist–hip ratio (WHR) was 
above the normal range for both men and women [28].
The ANA test was positive in 260 patients (15.0%) of the 
entire study population. Of the 733 participants for whom 
a cutoff threshold of 1:100 was used, 19.5% (n = 143) had 
a positive result for ANA. Only 27 patients in this group 
had titers higher than 1:100. In the second group, consist-
ing of 998 participants with a 1:160 cutoff threshold, the 
percentage of ANA-positive results was clearly lower, at 
11.7% (n = 117). 32 patients in this group had titers higher 
than 1:160. Frequency analysis comparing the 1:100 
and 1:160 groups in terms of final ANA titer is shown in 
Table 1  Characteristics of the 
population







Mean SD Mean SD Mean SD
Age 51.0 13.0 50.4 13.1 51.6 12.9
Height (cm) 168 9.15 177 6.71 163 6.05
Weight (kg) 80.2 17.1 91.2 15.2 73.0 14.1
BMI (kg/cm2) 28.2 5.05 29.3 4.50 27.5 5.29
Waist circumference (cm) 94 14.3 101 12.0 89.3 13.6
Hip circumference (cm) 105 10.8 105 9.33 105 11.7
WHR 0.89 0.09 0.96 0.07 0.85 0.07
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Fig. 1. ANA-staining patterns corresponding to ICAP are 
in Table 2. We present summary data for both subgroups 
because the cutoff titer used did not significantly affect the 
distribution of detected types of staining. The most fre-
quent ANA-staining pattern was AC-2 Dense Fine speckled 
(50%) followed by AC-21 Reticular/AMA (15.4%) and AC4/
AC5—Fine/Large/Coarse Speckled (14.6%). 
The relationship between sex and the occurrence of 
autoantibodies is shown in Table 3. In the tested group, 
women had an 84% higher risk of a titer of 1:100 than men, 
and at higher titres the risk was even higher, ranging from 
2-fold (for a titer of 1:160) to 3.3-fold (for a titer of 1:640). 
In general, there were no significant differences in the types 
of patterns detected in either sex, but with a few notable 
exceptions. AC4/AC5 antibodies were more than four times 
as common in women (OR = 4.46) and AC-2 was more than 
twice as common (OR = 2.33). In contrast, AC-9/AC-10 
were more than twice as common in men (OR = 0.42).
Characteristics of the participants based on the occur-
rence of ANA are presented in Table 4 which shows that 
significant factors for ANA positivity include age and gen-
der. Women have an 81% higher risk of positive ANA than 
men (OR = 1.81 CI 1.35–2.42). Each 1-year increase in age 
is associated with a 2% (OR = 1.02 CI = 1.01–1.03) increase 
in the risk of ANA positivity. No correlation was found 
between the occurrence of autoantibodies and broader car-
diovascular disease and lipid disorders. Autoantibodies were 
more frequently detected in the elderly (p < 0.001)—Table 4, 
differences for individual age ranges are shown in Table 5. In 
the entire studied population, the lowest percentage of ANA-
positive individuals was observed in those under 30 years 
of age (7.9%), and the highest proportions of ANA-positive 
people were in those aged 60–70 (20.6%) and over 70 years 
(22.4%). 84% of ANA-positive individuals were over 40 
(n = 219) and 64% were over 50 years of age (n = 167). 
Discussion
In our study, the prevalence of ANA in the Polish popula-
tion was 15%, similar to results observed in other developed 
countries. However, it is worth noting that the percentage of 
positive results is strongly dependent on the cutoff threshold 
used. Therefore, to reduce the number of positive results 
released by Polish laboratories, we suggest that a serum 
dilution of 1:160 be used for screening purposes, especially 
since it is very rare for individuals with lower ANA titers to 
have clinical symptoms [20, 29]. However, for official rec-
ommendations to be made, it would be necessary to conduct 
additional studies to collect additional data on the diagnos-
tic sensitivity and specificity of this approach in a group 
of patients diagnosed with SARD. Therefore, this proposal 
should not be considered as an official recommendation to 
laboratories.
Prevalence of ANA in the Polish population 
and the influence of the cutoff threshold used
The prevalence of ANA in the general population is com-
mon, and depending on the cutoff threshold used by inves-
tigators, can reach up to 30.8% [22]. The aim of the present 
study was to determine the prevalence of ANA in Polish 
population based upon on the cutoff threshold used and the 
influence of patient sex and age on the results. A total of 
1731 samples were tested, and ANA were detected in 15%. 

























Fig. 1  Frequency analysis comparing the 1:100 and 1:160 groups 
(n = 260) in terms of final ANA titer
Table 2  Frequency distribution of ANA patterns
AC anti-cell; AMA antimitochondrial antibodies; ICAP International 
Consensus on ANA patterns; NuMA nuclear mitotic apparatus




AC-2—dense fine speckled 130 50.00%
AC-3—centromere 3 1.15%
AC4/AC5—fine/large/coarse speckled 38 14.62%
AC6/AC7—multiple/few nuclear dots 3 1.15%
AC-8—homogenous nucleolar 1 0.38%
AC-9/AC-10—clumpy/punctate nucleolar 28 10.77%
AC11/AC12—smooth/punctate nuclear envelope 2 0.77%
AC-15—fibrillar linear 6 2.31%
AC-16—fibrillar filamentous 4 1.54%
AC-19/AC-20—dense fine/fine speckled 6 2.31%
AC-21—reticular/AMA 40 15.38%
AC-23—rods and rings 3 1.15%
AC-25/AC-26—spindle fibers/NuMA-like 4 1.54%
AC-27—intercellular bridge 2 0.77%
AC-28—mitotic chromosomal 1 0.38%
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researchers using a similar level of cutoff thresholds, e.g., 
in the previously mentioned studies of Maritz et al. ANA 
were present in 12.9% of healthy individuals at a 1:80 cut-
off titer [29]. Similar results were obtained by Prüßmann 
et al. who tested over 5000 healthy blood donors among 
which 17.7% were ANA positive [18] and Agmon-Levin 
et al. who reported 13.3% at the 1:80 cutoff titer [6]. ANA 
prevalence in the U.S. population aged ≥ 12 years was also 
similar at 13.8% (titer ≥ 1:80) [19]. A higher percentage of 
ANA was observed by Akmatov et al. in Germany, in which 
the general population was found to be positive for ANA in 
33.3% of individuals (titer ≥ 1:80) and 28.6% with a titer of 
1:80 or 1:160 [4].
The influence of the cutoff threshold used on the per-
centage of positive results is obvious. Therefore, our study 
assessed the impact of the initial cutoff dilution used in the 
Polish population on the number of positive results obtained. 
To assess the impact, the test group was divided into two 
subgroups. In the first group we used the cutoff threshold 
1:100 recommended by the test manufacturer. At this cutoff 
in the examined group of 733 samples, a positive result was 
observed in 19.5%. A 1:160 cutoff threshold, which is often 
found to be the most suitable for the evaluation of adult 
patients [6] was used in the second subgroup where the per-
centage of ANA-positive results was lower, at 11.7%. This 
downward has been observed in previous studies [4].
Low antibody titers are usually not clinically relevant and 
are rarely accompanied by clinical symptoms. In contrast, 
there is an increased likelihood of SARDs with higher ANA 
titer [4, 8]. Indeed, 13.5% of our participants had a titer of 
1:320, 6.45% titer 1:640 and 2.69% ≥ 1:1000, and these indi-
viduals may be at higher risk of developing or suffering from 
SARDs.
Prevalence of different types of pattern staining
As reported by Satoh et al. in ANA-positive individuals, 
nuclear patterns were seen in 84.6%, cytoplasmic patterns in 
21.8%, and nucleolar patterns in 6.1% [19]. Our results appear 
to show that according to the ICAP classification, nuclear 
staining was observed in 77%, cytoplasmic patterns in 20.6% 
and mitotic in 2.5%. The most frequent ANA-staining pat-
tern was AC-2 dense fine speckled (50%) followed by AC-21 
Reticular/AMA (15.38%) and AC4/AC5—Fine/Large/Coarse 
Table 3  Titers and types of autoantibody staining stratified on gender
Statistically significant data are in bold
AC anti-cell, ANA antinuclear antibody; AMA antimitochondrial antibodies; CI confidence interval; ICAP International Consensus on ANA pat-
terns; NuMA nuclear mitotic apparatus; OR odds ratio
Male Female P value OR  − 95% CI  + 95% CI
n = 688 n = 1043
Percentage Number Percentage Number
ANA titer 1:100 10.6% 73 17.9% 187  < 0.001 1.84 1.38 2.46
ANA titer 1:160 5.4% 37 10.3% 107  < 0.001 2.01 1.37 2.96
ANA titer 1:320 1.7% 12 4.5% 47 0.001 2.66 1.40 5.05
ANA titer 1:640 0.6% 4 1.9% 20 0.020 3.34 1.14 9.84
ANA titer 1:1000 0.1% 1 0.6% 6 0.168 3.97 0.48 33.21
AC4/AC5 fine/large/coarse speckled 0.7% 5 3.2% 33 0.001 4.46 1.73 11.51
AC-2 dense fine speckled 4.4% 30 9.6% 100  < 0.001 2.33 1.53 3.54
AC-9/AC-10 clumpy/punctate nucleolar 2.5% 17 1.1% 11 0.022 0.42 0.20 0.90
AC-1 homogenous 0.4% 3 0.7% 7 0.528 1.54 0.40 5.99
AC-3 centromere 0.1% 1 0.2% 2 0.820 1.32 0.12 14.61
AC6/AC7 multiple/few nuclear dots 0.1% 1 0.2% 2 0.820 1.32 0.12 14.61
AC11/AC12 smooth/punctate nuclear envelope 0.1% 1 0.1% 1 0.767 0.66 0.04 10.58
AC-15 fibrillar linear 0.6% 4 0.2% 2 0.177 0.33 0.06 1.80
AC-16 fibrillar filamentous 0.1% 1 0.3% 3 0.547 1.98 0.21 19.14
AC-19/AC-20 dense fine/fine speckled 0.4% 3 0.3% 3 0.607 0.66 0.13 3.28
AC-21 reticular/AMA 1.6% 11 2.8% 29 0.109 1.76 0.87 3.55
AC-23 rods and rings 0.1% 1 0.2% 2 0.820 1.32 0.12 14.61
AC-8 homogenous nucleolar 0.1% 1 0.0% 0 0.218 – – –
AC-25/AC-26 spindle fibers/NuMA-like 0.0% 0 0.4% 4 0.104 – – –
AC-27 intercellular bridge 0.3% 2 0.0% 0 0.082 – – –
AC-28 mitotic chromosomal 0.0% 0 0.1% 1 0.417 – – –
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Speckled (14.62%). The dense fine speckled pattern (AC-2) is 
associated with apparently healthy individuals, but this asso-
ciation only holds if the specificity is confirmed as monospe-
cific for DFS70 because the pattern recognized as AC-2 is 
not always induced by anti-DFS70 antibodies [30]. Miyara 
et al. showed also that the likelihood of anti-DFS70 antibod-
ies is significantly lower than in patients with other IIFA pat-
terns [31]. Due to the fact that the AC-2 pattern was detected 
in half of the samples tested, an interesting issue requiring 
further testing would be an assessment of the prevalence of 
anti-DFS70 antibodies in the Polish population.
As mentioned, there were no significant differences for 
the types of pattern staining by gender except AC4/AC5 and 
AC-2 which were detected much more often in women than 
in men. In contrast, nucleolar type of staining AC-9/AC-10 
was more often detected in men.
The presence of ANA in relation to sex and age
It would be useful to link these data with information 
about the incidence of individual connective tissue 
diseases. Unfortunately, the survey completed by patients 
participating in the LIPIDOGRAM2015 and LIPI-
DOGEN2015 project did not include questions about 
SARDs. Furthermore, there are no relevant statistical 
surveys for the Polish population [32]. Among ANA-
positive individuals, there was a clear predominance of 
women over men, consistent with other worldwide obser-
vations [3, 5, 19].
On the one hand, it was shown that in the study group 
the risk of ANA positivity increases with each additional 
year of life by 2%, but on the other hand, this did not 
result in an apparent upward trend in the percentage of 
ANA positivity when comparing the following age groups 
when divided into 10-year age intervals. In 30- to 60-year-
old patients, the percentage of positive results remains at 
13.4–13.7% for each 10-year interval. Overall, 84% of 
ANA-positive patients were over 40 years of age and 64% 
over 50 years of age. Considering that the risk of ANA 
positivity in women is up to 81% higher, it is not surpris-
ing that in all age ranges, the percentage of ANA positivity 
in women is higher than in men.
Table 4  Demographic and clinical characteristics and the presence of ANA
Statistically significant data are in bold
ANA antinuclear antibodies; BMI body mass index; CI confidence interval; OR odds ratio; WHR waist–hip ratio
ANA negative ANA positive Change% P value OR  − 95% CI  + 95% CI
n = 1471 n = 260
Mean/% SD/n Mean/% SD/n
Genders (% of men) 42% 615 28% 73  < 0.001 1.84 1,38 2,46
Age (years) 51 13 54 12 6%  < 0.001 1.02 1,01 1,03
Height (cm) 169 9.2 166 8.3 −1%  < 0.001 0.97 0,95 0,98
Weight (kg) 80.7 17.2 77.6 16.2 −4% 0.008 0.99 0,98 1,00
BMI (kg/m2) 28.2 5.05 28.0 5.11 −1% 0.513 0.99 0,97 1,02
Waist circumference (cm) 94.1 14.4 93.0 13.6 −1% 0.257 0.99 0,99 1,00
Hip circumference (cm) 105.0 10.8 105.6 11.1 1% 0.381 1.01 0,99 1,02
WHR 0.90 0.09 0.88 0.08 −2% 0.013 0.16 0,04 0,68
Chronic kidney disease 2.7% 40 1.5% 4 0.265 0.56 0,20 1,58
Coronary artery disease 10.3% 152 11.2% 29 0.690 1.09 0,71 1,66
Myocardial infarction 4.1% 61 4.2% 11 0.950 1.02 0,53 1,97
Ischemic stroke 1.5% 22 1.9% 5 0.608 1.29 0,48 3,44
Hemorrhagic stroke 0.3% 4 0.4% 1 0.755 1.42 0,16 12,73
Atrial fibrillation 2.8% 41 4.2% 11 0.209 1.54 0,78 3,04
Dyslipidemia 49.4% 726 51.9% 135 0.445 1.11 0,85 1,44
Family hypercholesterolemia 3.7% 55 2.3% 6 0.249 0.61 0,26 1,43
Diabetes mellitus 15.6% 229 19.2% 50 0.139 1.29 0,92 1,81
Arterial hypertension 42.1% 619 47.7% 124 0.092 1.25 0,96 1,64
Healthy individuals 36.3% 534 38.1% 99 0.584 1.08 0,82 1,42
Multivariable-adjusted logistic regression analysis
Genders (% of men)  < 0.001 1.81 1.35 2.42
Age (years)  < 0.001 1.02 1.01 1.03
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Most people with a positive ANA are not diagnosed 
with autoimmune disease, and the probability of future 
disease is low [20] but, as shown by Jonsson et al., some-
times the production of specific autoantibodies (AAb) pre-
cedes the symptoms and diagnosis of connective tissue 
diseases [33].
Limitations
The present study is limited by a lack of data about the 
clinical symptoms of SARDs among the participants, so 
we could not compare the results obtained with any clinical 
manifestations. To assess the real clinical relevance of the 
antibodies we detected, details of symptoms experienced 
by participants would be necessary. Future studies by our 
research group will also determine the prevalence of anti-
DFS70 antibodies in the Polish population and their correla-
tion with gender and clinical symptoms in patients.
In conclusion, ANA prevalence in the Polish population 
is similar to that observed in other highly developed coun-
tries. In the Polish population, ANAs are more prevalent in 
women and with elderly individuals. The cutoff threshold 
used in the laboratory has a considerable impact on the per-
centage of positive results obtained. To reduce the number 
of positive results released, we suggest that Polish laborato-
ries should set 1:160 as the cutoff threshold. However, more 
studies are needed before this threshold can be incorporated 
within practice guidelines.
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